Semaglutide can interact with certain medications, particularly other antidiabetic drugs, which may increase the risk of hypoglycemia
Control of compulsive behavior, 4
Patient safety advice includes: Report persistent vomiting or signs of dehydration promptly to your healthcare provider Seek urgent medical care for severe abdominal pain, especially if radiating to the back Be aware of symptoms of hypoglycaemia if taking other diabetes medications Inform your doctor if you are planning pregnancy, as GLP-1 receptor agonists should be discontinued (at least 2 months before planned pregnancy for semaglutide) [1] [7] Attend regular follow-up appointments to monitor treatment response and side effects Suspected adverse reactions should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
Potential Risks: While L-carnitine is beneficial for energy metabolism, excessive intake might lead to increased TMAO levels, which have been associated with cancer and heart disease in some studies
These outcomes underpin guideline support from the American Diabetes Association, which in its 2024 Standards of Care lists liraglutide as a preferred agent when cardiovascular risk reduction is a treatment goal [6]